Search - tctmd.com

Displaying 61 - 80 of 92

Sort: Relevancy | Date

News Daily News

CoreValve US Subanalysis: Only Femoral TAVR Offers Early QoL Advantage Over Surgery

L.A. McKeown

August 19, 2015

News Daily News

Incluso con Más Experiencia la TAVR Transapical No ofrece una Mejor Calidad de Vida que la Cirugía

Caitlin E. Cox

June 15, 2015

News Daily News

Even With More Experience, Transapical TAVR Offers No Better QoL Than Surgery

Caitlin E. Cox

June 15, 2015

News Daily News

TAVR可改善大多数高危患者的健康相关生活质量

L.A. McKeown

February 19, 2015

News Daily News

TAVR Mejora la Calidad de Vida asociada a la Salud en la Mayoría de Pacientes de Riesgo Extremo

L.A. McKeown

February 19, 2015

News Daily News

TAVR Improves Health-Related QoL in Majority of Extreme-Risk Patients

L.A. McKeown

February 19, 2015

Presentation TCT 2014

CLEAN-TAVI: A Prospective, Randomized Trial of Cerebral Embolic Protection in High-Risk Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Presenter: Patrick W. Serruys, David J. Cohen, Axel Linke

September 13, 2014

Presentation TCT 2014

US CoreValve High Risk Trial: Cost-Effectiveness Analysis From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Self-Expanding Device Versus Surgical Aortic Valve Replacement in High-Risk Patients with Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen, Matthew R. Reynolds

September 13, 2014

Presentation TCT 2014

PARTNER I: Five-Year Results From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Balloon-Expandable Device Versus Conservative Care in Extremely High-Risk Patients with Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen, Samir R. Kapadia

September 13, 2014

News Daily News

Treatment Delays May Undermine TAVR Efficacy

June 11, 2014

News Daily News

Los Retrasos en el Tratamiento Podrían Minar la Eficacia de la TAVR

June 11, 2014

Presentation TVT 2014

The TAVR Economic Value Proposition The Impact of Valve Costs, Complications, QOL Benefits, and Reimbursement Strategies

Presenter: David J. Cohen

June 07, 2014

Presentation TCT 2013

A Critical Analysis of Functional Improvement after TAVR in the CoreValve US Extreme Risk Study

Presenter: David Cohen

October 29, 2013

Presentation TCT 2013

A Synthesis of the Global Literature on TAVR Cost-effectiveness

Presenter: David Cohen

October 28, 2013

News Daily News

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

July 25, 2013

News Daily News

En Pacientes Inoperables, la TAVR produce Beneficios pero Dispara el Gasto de por Vida

July 25, 2013

Presentation TVT 2013

Can We Afford TAVR? Impact on US Hospitals and Health Systems: Lessons from PARTNER and Beyond

Presenter: David Cohen

June 13, 2013

Presentation TVT 2013

TAVR Cost-effectiveness and Reimbursement: A Global Gordian Knot

Presenter: David Cohen

June 12, 2013

Presentation TCTAP 2013

Can We Afford TAVR? Economic Insights from the PARTNER Trial

Presenter: David J. Cohen

April 25, 2013

Presentation TCT 2013

Predictors of Vascular complications in patients undergoing Balloon Aortic Valvuloplasty

Presenter: Annapoorna Kini, Roxana Mehran, Nilusha Gukathasan, Ziad Sergie, Mauricio Cohen, Jennifer Yu, Usman Baber, Samantha Sartori, Robert Pyo, Kleanthis Theodoropoulos, Roja Thapi, Elliot Elias, Socrates Kakoulides, Evan Jocobs, David knopf, Jason Kovacic, Raj Vadde, Brian O'Neill, Samin Sharma, George Dangas

January 31, 2013

Advertisement

CoreValve US Subanalysis: Only Femoral TAVR Offers Early QoL Advantage Over Surgery

Incluso con Más Experiencia la TAVR Transapical No ofrece una Mejor Calidad de Vida que la Cirugía

Even With More Experience, Transapical TAVR Offers No Better QoL Than Surgery

TAVR可改善大多数高危患者的健康相关生活质量

TAVR Mejora la Calidad de Vida asociada a la Salud en la Mayoría de Pacientes de Riesgo Extremo

TAVR Improves Health-Related QoL in Majority of Extreme-Risk Patients

CLEAN-TAVI: A Prospective, Randomized Trial of Cerebral Embolic Protection in High-Risk Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

US CoreValve High Risk Trial: Cost-Effectiveness Analysis From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Self-Expanding Device Versus Surgical Aortic Valve Replacement in High-Risk Patients with Aortic Stenosis

PARTNER I: Five-Year Results From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Balloon-Expandable Device Versus Conservative Care in Extremely High-Risk Patients with Aortic Stenosis

Treatment Delays May Undermine TAVR Efficacy

Los Retrasos en el Tratamiento Podrían Minar la Eficacia de la TAVR

The TAVR Economic Value Proposition The Impact of Valve Costs, Complications, QOL Benefits, and Reimbursement Strategies

A Critical Analysis of Functional Improvement after TAVR in the CoreValve US Extreme Risk Study

A Synthesis of the Global Literature on TAVR Cost-effectiveness

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

En Pacientes Inoperables, la TAVR produce Beneficios pero Dispara el Gasto de por Vida

Can We Afford TAVR? Impact on US Hospitals and Health Systems: Lessons from PARTNER and Beyond

TAVR Cost-effectiveness and Reimbursement: A Global Gordian Knot

Can We Afford TAVR? Economic Insights from the PARTNER Trial

Predictors of Vascular complications in patients undergoing Balloon Aortic Valvuloplasty

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content